<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4119">
  <stage>Registered</stage>
  <submitdate>5/06/2013</submitdate>
  <approvaldate>5/06/2013</approvaldate>
  <nctid>NCT01872689</nctid>
  <trial_identification>
    <studytitle>A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)</studytitle>
    <scientifictitle>A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-001163-24</secondaryid>
    <secondaryid>GB28547</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Idiopathic Pulmonary Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Lebrikizumab
Treatment: drugs - Pirfenidone
Treatment: drugs - Placebo

Experimental: Cohort A: Monotherapy Lebrikizumab - Monotherapy of lebrikizumab 250 milligrams (mg) will be administered SC once every 4 weeks up to 52 weeks placebo-controlled treatment period, and thereafter for an additional 52 weeks (i.e., up to Week 104) in the open-label period.

Placebo Comparator: Cohort A: Monotherapy Placebo - Placebo matched to lebrikizumab will be administered SC once every 4 weeks up to 52 weeks placebo-controlled treatment period. Thereafter, will be followed by lebrikizumab 250 mg administered SC every 4 weeks for additional for 52 weeks (i.e., up to Week 104) in the open-label period.

Experimental: Cohort B: Combination Therapy (Lebrikizumab + Pirfenidone) - Pirfenidone less than or equal to (&lt;=) 2403 mg once daily (maximum tolerated dose) will be administered in combination with lebrikizumab 250 mg SC once every 4 weeks up to 52 weeks placebo-controlled treatment period.

Placebo Comparator: Cohort B: Combination Therapy (Placebo + Pirfenidone) - Pirfenidone &lt;= 2403 mg once daily (maximum tolerated dose) will be administered in combination with placebo matched to lebrikizumab SC once every 4 weeks up to 52 weeks placebo-controlled treatment period.


Treatment: drugs: Lebrikizumab
Administered SC every 4 weeks

Treatment: drugs: Pirfenidone
Administered daily at the maximum tolerated dose

Treatment: drugs: Placebo
Administered SC every 4 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Annualized Rate of Decrease in Percent Predicted Forced Vital Capacity (FVC) Over 52 Weeks</outcome>
      <timepoint>Baseline up to Week 52</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-Free Survival (PFS) Defined as Time From Randomization to Death, All Cause Hospitalization, or a Decrease From Baseline of Greater Than or Equal to (&gt;=) 10 Percent (%) in FVC, Whichever Occurs First</outcome>
      <timepoint>Baseline up to 18 weeks after last dose (last dose = Week 104)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Annualized Rate of Decrease in FVC (in Milliliters [mL] per Year) Over 52 Weeks</outcome>
      <timepoint>Baseline up to Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to First Occurrence of a &gt;= 10% Absolute Decline in Percent Predicted FVC or Death From Any Cause</outcome>
      <timepoint>Baseline up to 18 weeks after last dose (last dose = Week 104) or death from any cause, whichever occurs first</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Annualized Rate of Decrease in Diffusion Capacity of the Lung for Carbon Monoxide (DLco) Over 52 Weeks</outcome>
      <timepoint>Baseline up to Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Annualized Rate of Decrease in A Tool to Assess Quality of Life in IPF (ATAQ-IPF) Questionnaire Total Score Over 52 Weeks</outcome>
      <timepoint>Baseline up to Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Non-elective Hospitalization or Death From Any Cause</outcome>
      <timepoint>Baseline up to 18 weeks after last dose (last dose = Week 104) or death from any cause, whichever occurs first</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Annualized Rate of Decline in 6-Minute Walk Test (6MWT) Distance Over 52 Weeks</outcome>
      <timepoint>Baseline up to Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to First Event of Acute IPF Exacerbation</outcome>
      <timepoint>Baseline up to 18 weeks after last dose (last dose = Week 104)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to First Occurrence of St. George's Respiratory Questionnaire (SGRQ) Total Score Worsening (Defined as Total Score = 7 or Death From Any Cause)</outcome>
      <timepoint>Baseline up to 18 weeks after last dose (last dose = Week 104) or death from any cause, whichever occurs first</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Adverse Events or Serious Adverse Events</outcome>
      <timepoint>Baseline up to 18 weeks after last dose (last dose = Week 104)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Anti-therapeutic Antibody (ATA) to Lebrikizumab</outcome>
      <timepoint>Baseline up to 18 weeks after last dose (last dose = Week 104)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum Lebrikizumab Concentration at Week 52 (Cwk52)</outcome>
      <timepoint>Pre-dose (at Hour 0) at Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minimum Observed Serum Trough Lebrikizumab Concentration (Cmin)</outcome>
      <timepoint>Pre-dose (at Hour 0) at Weeks 4, 12, 24, and 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Elimination Half-Life (t1/2) of Lebrikizumab</outcome>
      <timepoint>Pre-dose (at Hour 0) at Weeks 1, 4, 12, 24, 36, 64, 76, 88, 104; at 4, 12, and 18 weeks post-last dose (last dose = Week 104)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have a diagnosis of IPF within the previous 5 years from time of screening and
             confirmed at baseline

          -  FVC &gt;=40 % and &lt;= 100% predicted at screening

          -  Stable baseline lung function as evidenced by a difference of less than (&lt;) 10% in FVC
             (liters) measurements between screening and Day 1, Visit 2 prior to randomization

          -  DLco &gt;=25% and &lt;=90% predicted at screening

          -  Ability to walk &gt;=100 meters unassisted in 6 minutes

          -  Cohort A: No background IPF therapy for &gt;=4 weeks allowed prior to randomization and
             throughout the placebo-controlled study period

          -  Cohort B: Tolerated dose of pirfenidone &lt;=2403 milligrams once daily (mg/QD) for &gt;=4
             weeks required prior to randomization and throughout the placebo-controlled study
             period</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of severe allergic reaction or anaphylactic reaction to a biologic agent or
             known hypersensitivity to any component of the lebrikizumab injection

          -  Evidence of other known causes of interstitial lung disease

          -  Lung transplant expected within 12 months of screening

          -  Evidence of clinically significant lung disease other than IPF

          -  Post-bronchodilator forced expiratory volume in 1 second (FEV1)/FVC ratio &lt; 0.7 at
             screening

          -  Positive bronchodilator response, evidenced by an increase of &gt;=12% predicted and 200
             mL increase in FEV1 or FVC

          -  Class IV New York Heart Association chronic heart failure or historical evidence of
             left ventricular ejection fraction &lt;35%

          -  Hospitalization due to an exacerbation of IPF within 4 weeks prior to or during
             screening

          -  Known current malignancy or current evaluation for potential malignancy

          -  Listeria monocytogenes infection or active parasitic infection within 6 months prior
             to Day 1, Visit 2

          -  Active tuberculosis requiring treatment within 12 months of screening

          -  Known immunodeficiency, including but not limited to human immunodeficiency virus
             infection

          -  Past use of any anti-interleukin (IL)-13 or anti-IL-4/IL-13 therapy, including
             lebrikizumab

          -  Evidence of acute or chronic hepatitis or known liver cirrhosis

        Exclusions Limited to Cohort B:

          -  Known achalasia, esophageal stricture, or esophageal dysfunction sufficient to limit
             the ability to swallow oral medication

          -  Tobacco smoking or use of tobacco-related products within 3 months of screening or
             unwillingness to avoid smoking throughout the study period

          -  Known or suspected peptic ulcer

          -  Any condition that, as assessed by the investigator, might be significantly
             exacerbated by the known side effects associated with pirfenidone

          -  Creatinine clearance &lt;40 mL/minute, calculated using the Cockcroft-Gault formula

          -  Use of following therapies within 4 weeks of randomization (Day 1, Visit 2) or during
             the study: Strong inhibitors of CYP1A2 (Cytochrome P450 Family 1 Subfamily A Member 2)
             (example: fluvoxamine or enoxacin); Moderate inducers of CYP1A2 (limited to tobacco
             smoking and tobacco-related products)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>13/10/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>507</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>15/11/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,WA</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital; Department of Respiratory Medicine - Camperdown</hospital>
    <hospital>ST VINCENT'S HOSPITAL; Thoracic Medicine - Darlinghurst</hospital>
    <hospital>Box Hill Hospital; Eastern Clinical Research Unit - Box Hill</hospital>
    <hospital>Alfred Hospital; Allergy Immuno Resp - Melbourne</hospital>
    <hospital>Institute for Respiratory Health Inc - Nedlands</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Vermont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Mont-godinne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bobigny</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gießen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Großhansdorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Immenhausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piemonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Sicilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Seto-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Hermosillo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Zabrze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will
      evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background
      IPF therapy or as combination therapy with pirfenidone background therapy in participants
      with IPF. Participants will be randomized to receive either lebrikizumab or placebo
      subcutaneously (SC) every 4 weeks.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01872689</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>